CLDN6 and neoplasm: In addition, GEN1046 significantly enhanced CLDN6-TCR+ T-cell–mediated cytotoxicity of MDA-MB-231 tumor cells more efficiently than atezolizumab or combinations of monovalent bsAb controls (Fig. 1J and K).